文献速递艾滋病与性传播感染

VH4524184概念验证2a期试验:一种具有增强耐药谱的新兴第三代整合酶链转移抑制剂

Proof-of-Concept Phase 2a Trial of VH4524184: An Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile.
PubMed 文献 · Clin Infect Dis · 2026-01-01

VH-184是一种新兴第三代整合酶链转移抑制剂,在体外对耐药病毒有增强活性,拟开发为长效抗逆转录病毒治疗。这项随机双盲安慰剂对照2a期试验在未治疗HIV-1成人中评估口服VH-184单药治疗,结果显示10、50、300 mg组HIV-1 RNA最大降幅分别为-1.17、-2.15和-2.31 log10 copies/mL,安全耐受性良好,未检出耐药。

要点

  • VH-184单药在10天内呈剂量依赖性快速抑制HIV-1 RNA。
  • 未发生导致退出或治疗相关严重不良事件,安全性良好。
  • 至第10天未检出VH-184基因型或表型耐药。

核心结论

  • VH-184单药治疗显示快速强效抗病毒活性及良好安全耐受性,支持其作为完整ART方案核心药物继续开发。

研究设计与样本

  • 随机双盲安慰剂对照2a期试验,入组22例未接受ART且HIV-1 RNA≥3000 copies/mL的成人,VH-184组19例、安慰剂组3例。
  • 参与者于第1、4、7天口服VH-184 10、50或300 mg或安慰剂,第10天启动标准ART。

主要发现

  • 第10天HIV-1 RNA自基线平均最大降幅:VH-184 10 mg为-1.17 log10 copies/mL,50 mg为-2.15 log10 copies/mL,300 mg为-2.31 log10 copies/mL。
  • 未发生导致退出的不良事件、治疗相关严重不良事件或死亡,安全性实验室参数、心电图及生命体征无临床相关变化。
  • 至第10天未检出VH-184基因型或表型耐药。

关键数值与推荐

  • 入组标准:未接受ART的成人,HIV-1 RNA≥3000 copies/mL。
  • 主要终点:第10天HIV-1 RNA自基线最大变化。
  • VH-184给药方案:第1、4、7天口服10、50或300 mg。

临床怎么用

  • 该早期数据支持VH-184作为长效ART核心药物的进一步开发,尚不能用于临床处方决策。

局限性

  • 样本量小(22例),仅评估单药短期治疗至第10天,需后续完整ART方案研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: VH4524184 (VH-184) is an emerging third-generation integrase strand transfer inhibitor (INSTI) with an enhanced in vitro resistance profile compared with second-generation INSTIs being developed as a long-acting antiretroviral therapy (ART) for human immunodeficiency virus type 1 (HIV-1). We present data from a proof-of-concept phase 2a trial of VH-184 in people with HIV-1. METHODS: This randomized, double-blind, placebo-controlled trial evaluated oral VH-184 monotherapy in adults naive to ART with HIV-1 RNA ≥ 3000 copies/mL. Participants received oral VH-184 10, 50, or 300 mg or placebo on days 1 (baseline), 4, and 7. On day 10, participants initiated standard-of-care ART. The primary endpoint was maximum change from baseline in plasma HIV-1 RNA through day 10. Secondary endpoints included safety, tolerability, exposure-response relationship, CD4+ cell effects, and treatment-emergent resistance. RESULTS: Of 22 participants enrolled (VH-184, n = 19; placebo, n = 3), 86% were male, 68% were White, and median age was 32 years. Mean maximum change from baseline through day 10 in HIV-1 RNA was -1.17, -2.15, and -2.31 log10 copies/mL for VH-184 10, 50, and 300 mg, respectively. No adverse events (AEs) leading to withdrawal, treatment-emergent serious AEs, or deaths occurred. There were no clinically relevant changes in safety laboratory parameters, electrocardiograms, or vital signs. No VH-184 genotypic or phenotypic resistance was detected through day 10. CONCLUSIONS: Monotherapy with VH-184 demonstrated rapid and potent antiviral activity and a favorable safety and tolerability profile. The established exposure-response model and efficacy and safety results support further development of VH-184 as the core agent in complete ART regimens for HIV-1 (ClinicalTrials.gov, NCT06214052).

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Rogg L, Nuñez SA, Mingrone MV, et al. Proof-of-Concept Phase 2a Trial of VH4524184: An Emerging Third-Generation Integrase Strand Transfer Inhibitor With an Enhanced Resistance Profile. Clin Infect Dis. 2026. PMID: 42283218. doi:10.1093/cid/ciag357

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。